The estimated Net Worth of Jason Lettmann is at least $14 Milion dollars as of 14 March 2024. Jason Lettmann owns over 4,400 units of ALX Oncology stock worth over $374,132 and over the last 8 years Jason sold ALXO stock worth over $13,600,564.
Jason has made over 4 trades of the ALX Oncology stock since 2016, according to the Form 4 filled with the SEC. Most recently Jason bought 4,400 units of ALXO stock worth $49,764 on 14 March 2024.
The largest trade Jason's ever made was buying 393,923 units of ALX Oncology stock on 31 October 2016 worth over $5,120,999. On average, Jason trades about 86,934 units every 269 days since 2016. As of 14 March 2024 Jason still owns at least 171,620 units of ALX Oncology stock.
You can see the complete history of Jason Lettmann stock trades at the bottom of the page.
Jason's mailing address filed with the SEC is C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at ALX Oncology have traded over $32,891,459 worth of ALX Oncology stock and bought 1,414,400 units worth $27,854,124 . The most active insiders traders include G. Walmsley Graham, Jack Nielsen a Capital Ix, Llc Vivo Capita.... On average, ALX Oncology executives and independent directors trade stock every 22 days with the average trade being worth of $89,694. The most recent stock trade was executed by Shelly Pinto on 14 August 2024, trading 564 units of ALXO stock currently worth $1,455.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
ALX Oncology executives and other stock owners filed with the SEC include: